Mesenchymal stromal cells in aplastic anemia, hematological malignancies and not hematological tumors
Abstract
The results of the study on mesenchymal stromal cells (MSC) in aplastic anemia (AA), hemoblastosis and not hematological tumors have been analyzed. The data testifying for the involvement of hematopoietic niches in the pathological process in AA and hematological malignancies as well as the facts confirming that the elements of the microenvironment can be the original cause of hematological diseases have been given.. The analysis of the results of study on the MSC influence on the tumor growth and metastasis has been carried out. The inconsistency of obtained data has been noted. It is shown that MSC can have both stimulating and inhibiting effect, possible mechanisms underlying these processes are discussed. It has been concluded that the better understanding of the MSC biology and their role in the onset and progression of various pathological conditions can become the basis for the development of new programs for the treatment of hematological and oncological diseases.
Key words
1. Bessmeltsev S.S. Multiple myeloma (pathogenesis, clinical features, diagnosis, differential diagnosis). Part 1 // Klinicheskaya onkogematologiya. 2013. 6. (3). 237–58. (in Russian)
2. Gerasimova L.P., Drise N.I., Lubkova O.N. et al. Stromal microenvironment disturbance of pathients with various diseases of the blood system // Gematologiya i transfuziologiya. 2008. 53. (5). 59–62. (in Russian)
3. Rugal V.I., Ponomarenko V.M., Abdylkadirov K.M. Structural features hemopoietic microenvironment for aplastic anemia // Meditsinskiy akademicheskiy zhurnal. 2004. 4. (1). 36–41. (in Russian)
4. Chertkov I.L., Gyrievich O.A. Stem cell and microenvironment. Moscow: Medicine, 1984. (in Russian)
5. Shevela E.Ya., Petrovskii Ya.L., Kurganova E.V. Characteristic of mesenchymal stromal cells of bone marrow of patients with hemoblastosis // Gematologiya i transfuziologiya. 2008. 53. (2). 32–37. (in Russian)
6. Shevela E.Ya., Kulagin A.D., Tichonova M.A. et al. Aplastic anemia: phenotype and functions of bone marrow mesenchymal stromal cells // Gematologiya i transfuziologiya. 2010. 55. (6). 14–21. (in Russian)
7. Attasi Y., Mowla S.J., Ziaee S.A. et al. Oct-4, an embryonic stem cell marker, is highly expressed in bladder cancer // Int. J. Cancer. 2007. 120. 1598–1602.
8. Bacigalupo A., Valle M., Podestà M. et al. T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia // Exp. Hematol. 2005. 33. (7). 819–827.
9. Bergfeld S.A., DeClerck Y.A. Bone marrow-derived mesenchymal stem cells and the tumor microenvironment // Cancer Metastasis Rev. 2010. 29. 249–261.
10. Blau O., Hofmann W.K., Baldus C.D. et al. Chromosomal aberrations in bone marrow mesenchymalstroma cells from patients with myelodysplastic syndrome and acute myeloblasticleukemia // Exp. Hematol. 2007. 35. (2). 221–229.
11. Campioni D., Bardi M.A., Cavazzini F. et al. Cytogenetic and molecular cytogenetic profile of bone marrow-derived mesenchymal stromal cells in chronic and acute lymphoproliferative disorders // Ann. Hematol. 2012. 91. (10). 1563–1577.
12. Campioni D., Lanza F., Moretti S. et al. Functional and immunophenotypic characteristics of isolated CD105(+) and fibroblast(+) stromal cells from AML: implications for their plasticity along endothelial lineage // Cytotherapy. 2003. 5. (1). 66–79.
13. Campioni D., Moretti S., Ferrari L. et al. Immunophenotypic heterogeneity of bone marrow-derived mesenchymal stromal cells from patients with hematologic disorders: correlation with bone marrow microenvironment // Haematologica. 2006. 91. (3). 364–368.
14. Carlo-Stella C., Tabilio A., Regazzi E. et al. Effect of chemotherapy for acute myelogenous leukemia on hematopoietic and fibroblast marrow progenitors // Bone Marrow Transplant. 1997. 20. (6). 465–471.
15. Chiou S.H., Yu C.C., Huang C.Y. et al. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma // Clin. Cancer Res. 2008. 14. 4085–4095.
16. Flores-Figueroa E., Arana-Trejo R.M., Gutiérrez-Espíndola G. et al. Mesenchymal stem cells in myelodysplastic syndromes: phenotypic and cytogenetic characterization // Leuk. Res. 2005. 29. (2). 215–224.
17. Flores-Figueroa E., Varma S., Montgomery K. et al. Distinctive contact between CD34+ hematopoietic progenitors and CXCL12+ CD271+ mesenchymal stromal cells in benign and myelodysplastic bone marrow // Lab. Invest. 2012. 92. (9). 1330–1341.
18. Garayoa M., Garcia J.L., Santamaria C. et al. Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors // Leukemia. 2009. 23. (8). 1515–1527.
19. Geyh S., Oz S., Cadeddu R.P. et al. Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells // Leukemia. 2013. 27. (9). 1841–1851.
20. Gibbs C.P., Kukekov V.G., Reith J.D. et al. Stem-like cells in bone sarcomas: implications for tumorigenesis // Neoplasia. 2005. 7. 967–976.
21. Hall B., Andreeff M., Marini F. The participation of mesenchymal stem cells in tumor stroma formation and their application as targeted-gene delivery vehicles // Handb. Exp. Pharmacol. 2007. 180. 263–283.
22. Ho I.A., Toh H.C., Ng W.H. et al. Human bone marrow-derived mesenchymal stem cells suppress human glioma growth through inhibition of angiogenesis // Stem Cells. 2013. 31. (1). 146–155.
23. Hu J., Zhou Z., Shi Sh. et al. Mesenchymal stem-like cells isolated from human esophageal carcinoma and adjacent non-cancerous tissues // Oncology Letters. 2013. 5. 179–184.
24. Karnoub A.E., Dash A.B., Vo A.P. et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis // Nature. 2007. 449. 557–563.
25. Ke C.C., Liu R.S., Suetsugu A. et al. In vivo fluorescence imaging reveals the promotion of mammary tumorigenesis by mesenchymal stromal cells // PLoS. One. 2013. 8. (7). ID e69658.
26. Khakoo A.Y., Pati S., Anderson S.A. et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi’s sarcoma // J. Exp. Med. 2006. 203. 1235–1247.
27. Kidd S., Spaeth E., Dembinski J.L. et al. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging // Stem Cells. 2009. 27. 2614–2623.
28. Kidd S., Spaeth E., Watson K. et al. Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma // PLoS. One. 2012. 7. (2). ID e30563.
29. Kim J.H., Yoon S.Y., Kim C.N. et al. The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins // Cancer Lett. 2004. 203. 217–224.
30. Klopp A.H., Zhang Y., Solley T. et al. Omental adipose tissue-derived stromal cells promote vascularization and growth of endometrial tumors // Clin. Cancer Res. 2012. 18. (3). 771–782.
31. Kojima S., Matsuyama T., Kodera Y. Plasma levels and production of soluble stem cell factor by marrow stromal cells in patients with aplastic anaemia // Br. J. Haematol. 1997. 99. (2). 440–446.
32. Laine S.K., Hentunen T., Laitala-Leinonen T. Do microRNAs regulate bone marrow stem cell niche physiology? // Gene. 2012. 497. (1). 1–9.
33. Lechman E.R., Gentner B., van Galen P. et al. Attenuation of miR-126 activity expands HSC in vivo without exhaustion // Cell Stem Cell. 2012. 11. 799–811.
34. Lin R., Wang S., Zhao R.C. Exosomes from human adipose-derived mesenchymal stem cells promote migration through Wnt signaling pathway in a breast cancer cell model // Mol. Cell Biochem. 2013. 383. 13–20.
35. Lin T.M., Chang H.W., Wang K.H. et al. Isolation and identification of mesenchymal stem cells from human lipoma tissue // Biochem. Biophys. Res. Commun. 2007. 361. 883–889.
36. Liu L.H., Chen H., Chen B. et al. Immuno-suppressive effects on T cells mediated by mesenchymal stem cells from patients with myelodysplastic syndrome // Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008. 16. (2). 299–304.
37. Lopez-Villar O., Garcia J.L., Sanchez-Guijo F.M. et al. Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q-syndrome // Leukemia. 2009. 23. (4). 664–672.
38. Maeda K., Chung Y.S., Ogawa Y. et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma // Cancer. 1996. 77. 858–863.
39. McLean K., Gong Y., Choi Y. et al. Human ovarian carcinoma–associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production // J. Clin. Invest. 2011. 121. (8). 3206–3219.
40. Mishra P.J., Mishra P.J., Humeniuk R. et al. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells // Cancer Res. 2008. 68. 4331–4339.
41. Natsu K., Ochi M., Mochizuki Y. et al. Allogeneic bone marrow-derived mesenchymal stromal cells promote the regeneration of injured skeletal muscle without differentiation into myofibers // Tissue Eng. 2004. 10. 093–1112.
42. Qiao L., Xu Z., Zhao T. et al. Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model // Cell Res. 2008. 18. 500–507.
43. Raaijmakers M., Mukherjee S., Guo S.h. et al. Bone progenitor dysfunction induces myelodysplasia and leukemia // Nature. 2010. 464. (7290). 852–857.
44. Rajantie I., Ilmonen M., Alminaite A. et al. Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells // Blood. 2004. 104. 2084–2086.
45. Rappa G., Mercapide J., Lorico A. Spontaneous formation of tumorigenic hybrids between breast cancer and multipotent stromal cells is a source of tumor heterogeneity // Am. J. Pathol. 2012. 180. 2504-2515.
46. Roccaro A.M., Sacco A., Maiso P. et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma // J. Clin. Invest. 2013. 123. (4). 1542–1555.
47. Roela R.A., Carraro D.M., Brentani H.P. et al. Gene stage-specific expression in the microenvironment of pediatric myelodysplasticsyndromes // Leuk. Res. 2007. 31. (5). 579–589.
48. Rojas M., Xu J., Woods C.R et al. Bone marrow-derived mesenchymal stem cells in repair of the injured lung // Am. J. Respir. Cell Mol. Biol. 2005. 33. 145–152.
49. Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell // Blood Cells. 1978. 4. 7–25.
50. Sekiya I., Larson B.L., Smith J.R. et al. Expansion of human adult stem cells from bone marrow stroma: conditions that maximize the yields of early progenitors and evaluate their quality // Stem Cells. 2002. 20. (6). 530–541.
51. Shalapour S., Eckert C., Seeger K. et al. Leukemia-associated genetic aberrations in mesenchymal stem cells of children with acute lymphoblastic leukemia // J. Mol. Med. (Berl). 2010. 88. (3). 249–265.
52. Shinagawa K., Kitadai Y., Tanaka M. et al. Mesenchymal stem cells enhance growth and metastasis of colon cancer // Int. J. Cancer. 2010. 127. 2323–2333.
53. Spaeth E.L., Dembinski J.L., Sasser A.K. et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression // PLoS. One. 2009. 4. ID e4992.
54. Sun X., Cai H., Qian H. et al. Mesenchymal stem cells isolated from human uterine cervix cancer tissues // Cell Biol. Int. 2011. 35. 119–123.
55. Takanami I., Tanaka F., Hashizume T., Kodaira S. Vascular endothelial growth factor and its receptor correlate with angiogenesis and survival in pulmonary adenocarcinoma // Anticancer Res. 1997. 17. 2811–2814.
56. Walkley C.R., Olsen G.H., Dworkin S. et al. A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency // Cell. 2007. 129. (6). 1097–1110.
57. Wang H., Pan K., Zhang H.K. et al. Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma // J. Cancer Res. Clin. Oncol. 2008. 134. 535–541.
58. Wang Z., Tang X., Xu W. et al. The different immunoregulatory functions on dendritic cells between mesenchymal stem cells derived from bone marrow of patients with low-risk or high-risk myelodysplastic syndromes // PLoS. One. 2013. 8. (3). ID e57470.
59. Wu Y., Yu J., Zhang L. et al. Hematopoiesis support of mesenchymal stem cells in children with aplastic anemia // Zhongguo Dang Dai Er Ke Za Zhi. 2008. 10. (4). 455–459.
60. Xu X., Zhang X., Wang S. et al. Isolation and comparison of mesenchymal stem-like cells from human gastric cancer and adjacent non-cancerous tissues // Cancer Res. Clin. Oncol. 2011. 137. 495–504.
61. Yang S.M., Lu S.F., Fei X.M. et al. Change of cytokine expressions on bone marrow mesenchymal stem cells in patients with bone marrow failure syndromes and its significance // Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010. 18. (6). 1560–1563.
62. Zhao Z.G., Liang Y., Li K. et al. Phenotypic and functional comparison of mesenchymal stem cells derived from the bone marrow of normal adults and patients with hematologic malignant diseases // Stem Cells Dev. 2007. 16. (4). 637–648.
63. Zhao Z.G., Sun L., Wang X.F. et al. Immunomodulatory effects of mesenchymal stem cells derived from the bone marrow in acute leukemia patients // Zhonghua Zhong Liu Za Zhi. 2011. 33. (2). 05–109.
64. Zhao Z., Wang Z., Li Q. et al. The different immunoregulatory functions of mesenchymal stem cells in patients with low-risk or high-risk myelodysplastic syndromes // PLoS. One. 2012. 7. (9). ID e45675.
65. Zhang T., Lee Y.W., Rui Y.F. et al. Bone marrow-derived mesenchymal stem cells promote growth and angiogenesis of breast and prostate tumors // Stem Cell Res. Ther. 2013. 4. (3). ID PMC3707041.
66. Zhang Y.Z., Zhao D.D., Han X.P et al. In vitro study of biological characteristics of mesenchymal stem cells in patients with low-risk myelodysplasticsyndrome // Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008. 16. (4). 813–818.
Vartanyan N.L. – candidate of biological sciences, senior researcher of laboratory of hybridoma technology, e-mail: nvartanian@mail.ru.
Bessmeltsev S.S. – doctor of medical sciences, professor, deputy director on scientific work, e-mail: bsshem@hotmail.com.
Semenova N.Yu. – biologist, junior researcher of laboratory for the study of leukemia, e-mail: bloodscience@mail.ru
Rugal V.I. – doctor of medical sciences, professor, head of laboratory for the study of leukemia
